Allogeneic bone marrow transplantation in patients who relapse after autologous transplantation

被引:87
作者
Tsai, T
Goodman, S
Saez, R
Schiller, G
Adkins, D
Callander, N
Wolff, S
Freytes, CO
机构
[1] S TEXAS VET HLTH CARE SYST,SAN ANTONIO,TX
[2] NASHVILLE VET ADM MED CTR,NASHVILLE,TN
[3] UNIV OKLAHOMA,HLTH SCI CTR,OKLAHOMA CITY,OK
[4] UNIV CALIF LOS ANGELES,SCH MED,LOS ANGELES,CA
[5] WASHINGTON UNIV,SCH MED,ST LOUIS,MO
关键词
BMT; relapse; second transplant; lymphoma; leukemia;
D O I
10.1038/sj.bmt.1700989
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Increasing numbers of patients have received autologous stem cell transplants (ASCT) for hematologic malignancies, Since only a fraction of these patients are cured, physicians are more frequently faced with the dilemma of how to manage relapse post-transplant. Potential advantages of allogeneic transplantation (alloBMT) over ASCT include lack of graft tumor contamination and presence of a graft-versus-tumor effect, For this reason, patients who relapse after ASCT are often considered candidates for allogeneic bone marrow transplantation. However, there is limited knowledge on the outcome of alloBMT in patients who relapse after ASCT, We retrospectively analyzed the outcome of 20 patients with malignant lymphoma (n = 14) and AML (n = 6) who underwent alloBMT after failing an ASCT, The median age was 30 (17-41) years and the interval from ASCT to alloBMT was 10.5 (2-25) months, Seventeen patients died between 0.3 to 11 months (median 2.0) after alloBMT, all due to BMT-related toxicities, Three patients remain alive and free of disease at 1.1, 1.2 and 2.5 years after alloBMT. Sixteen of the 18 evaluable patients (89%) developed grade II-IV acute GVHD, Patients undergoing alloBMT after ASCT have a very high treatment-related mortality and incidence of grade II-IV acute GVHD, Alternative treatments with salvage chemotherapy, radiation or investigational approaches should be considered in patients who relapse after ASCT.
引用
收藏
页码:859 / 863
页数:5
相关论文
共 16 条
  • [1] TREATMENT OF MALIGNANT-LYMPHOMA IN 100 PATIENTS WITH CHEMOTHERAPY, TOTAL-BODY IRRADIATION, AND MARROW TRANSPLANTATION
    APPELBAUM, FR
    SULLIVAN, KM
    BUCKNER, CD
    CLIFT, RA
    DEEG, HJ
    FEFER, A
    HILL, R
    MORTIMER, J
    NEIMAN, PE
    SANDERS, JE
    SINGER, J
    STEWART, P
    STORB, R
    THOMAS, ED
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (09) : 1340 - 1347
  • [2] Chiang KY, 1996, BONE MARROW TRANSPL, V17, P39
  • [3] AUTOLOGOUS VERSUS ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR NON-HODGKINS-LYMPHOMA - A CASE-CONTROLLED ANALYSIS OF THE EUROPEAN-BONE-MARROW-TRANSPLANT-GROUP REGISTRY DATA
    CHOPRA, R
    GOLDSTONE, AH
    PEARCE, R
    PHILIP, T
    PETERSEN, F
    APPELBAUM, F
    DEVOL, E
    ERNST, P
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (11) : 1690 - 1695
  • [4] Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease
    Gajewski, JL
    Phillips, GL
    Sobocinski, KA
    Armitage, JO
    Gale, RP
    Champlin, RE
    Herzig, RH
    Hurd, DD
    Jagannath, S
    Klein, JP
    Lazarus, HM
    McCarthy, PL
    Pavlovsky, S
    Petersen, FB
    Rowlings, PA
    Russell, JA
    Silver, SM
    Vose, JM
    Wiernik, PH
    Bortin, MM
    Horowitz, MM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (02) : 572 - 578
  • [5] HOROWITZ MM, 1990, BLOOD, V75, P555
  • [6] JONES RJ, 1991, BLOOD, V77, P649
  • [7] KEITH MS, 1994, BONE MARROW TRANSPL, P339
  • [8] DONOR LEUKOCYTE TRANSFUSIONS FOR TREATMENT OF RECURRENT CHRONIC MYELOGENOUS LEUKEMIA IN MARROW TRANSPLANT PATIENTS
    KOLB, HJ
    MITTERMULLER, J
    CLEMM, C
    HOLLER, E
    LEDDEROSE, G
    BREHM, G
    HEIM, M
    WILMANNS, W
    [J]. BLOOD, 1990, 76 (12) : 2462 - 2465
  • [9] MACKINNON S, 1995, BLOOD, V86, P10
  • [10] Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease
    Milpied, N
    Fielding, AK
    Pearce, RM
    Ernst, P
    Goldstone, AH
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (04) : 1291 - 1296